The Exchange had sought clarification from Supriya Lifescience Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1.Segment details not submitted The response of the Company is enclosed.
SUPRIYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The stock exchange (NSE) had asked Supriya Lifescience to clarify why segment-wise details were missing from its financial results for the quarter ending 30 September 2025, under SEBI Listing Regulations. The company has now submitted its response to the exchange, likely providing the segment information that was earlier omitted. This is part of routine financial disclosure compliance and not a punitive action. The filing itself does not contain any numbers or business updates beyond the clarification submission.
Likely neutral for shareholders — this is a routine compliance exchange, not a penalty or regulatory action. Investors should check whether the company's response includes any new financial segment disclosures that could affect valuation or business outlook.